NeoCore Technology Co., Ltd. (TPEX:4131)
35.30
-0.20 (-0.56%)
Apr 20, 2026, 12:59 PM CST
NeoCore Technology Revenue
In the year 2025, NeoCore Technology had annual revenue of 244.66M TWD with 297.52% growth. NeoCore Technology had revenue of 66.17M in the quarter ending December 31, 2025, with 469.83% growth.
Revenue
244.66M
Revenue Growth
+297.52%
P/S Ratio
5.70
Revenue / Employee
5.56M
Employees
44
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 244.66M | 183.11M | 297.52% |
| Dec 31, 2024 | 61.55M | -3.18M | -4.92% |
| Dec 31, 2023 | 64.73M | -24.24M | -27.24% |
| Dec 31, 2022 | 88.97M | 42.00K | 0.05% |
| Dec 31, 2021 | 88.93M | -4.42M | -4.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 736.59M |
| Meribank Biotech | 471.76M |
| GenMont Biotech Incorporation | 401.23M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| Abnova (Taiwan) | 351.30M |
| GeneReach Biotechnology | 232.74M |
| Enimmune | 48.19M |
| Holy Stone Healthcare | 47.51M |